Table 4.

m6A regulator-targeted inhibitors

Target	Drug	Cancer	Effect	Ref.
METTL3	Adenosine analogues	NA	Reduces RNA m6A	[170]
	UZH1a	AML	Suppress proliferation and viability of tumor cells in vitro	[171]
	UZH2	AML, prostate cancer	More potent anti-proliferative effects in vitro	[172]
	STM2457	AML	Anti-leukemia efficacy in vitro and in vivo	[173]
FTO	Rhein	AML	Anti-leukemia efficacyin vitro and in vivo	[159]
	MA2	GBM	reduces GBM stem cell proliferation in vitro and tumor progression in mic	[160]
	CHTB	NA	Increases RNA m6A	[161]
	N-CDPCB	NA	Increases RNA m6A	[162]
	R-2HG	AML, GBM	Anti-leukemia efficacy in vitro and in vivo, suppresses GBM in viro, synergizes with chemotherapeutic drugs	[86]
	FB23-2	AML	Anti-leukemia efficacy in vitro and in vivo	[163]
	CS1 and CS2	AML	potent anti-leukemic efficacy in mouse models, sensitize leukemia cells to T-cell cytotoxicity, overcomes immune evasion	[150]
	Dac5	Melanoma	Promotes activation and effector state of T cell, improving anti-PD1 blockade effects	[151]
	FB23-13a	AML	Stronger anti-leukemia efficacy in vitro and in vivo	[164]
	18,097	Breast cancer	restrain in vivo growth and lung colonization	[165]
	FTO-43	GC, AML, GBM	Potent anti-tumor effects in mouse model	[166]
	Compound C6	Esophageal cancer	Anti-tumor efficacy in vitro and in vivo	[167]
		AML	Anti-leukemia and improves anti-PD1 blockade efficacy	[169]
ALKBH5	ALK-04	Melanoma	Improve anti-PD-1 therapy efficiency	[140]
	Compound 1 and 2	AML	Anti-proliferative effects in specific AML cell lines	[174]
IGF2BP1	BTYNB	Ovarian cancer	Anti-tumor efficacy in vitro and in vivo	[175]